[go: up one dir, main page]

WO2014141111A1 - Méthode permettant de prévenir et de traiter la maladie du greffon contre l'hôte - Google Patents

Méthode permettant de prévenir et de traiter la maladie du greffon contre l'hôte Download PDF

Info

Publication number
WO2014141111A1
WO2014141111A1 PCT/IB2014/059706 IB2014059706W WO2014141111A1 WO 2014141111 A1 WO2014141111 A1 WO 2014141111A1 IB 2014059706 W IB2014059706 W IB 2014059706W WO 2014141111 A1 WO2014141111 A1 WO 2014141111A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
stromal cells
adherent stromal
adherent
manufacture
Prior art date
Application number
PCT/IB2014/059706
Other languages
English (en)
Inventor
Zami Aberman
Original Assignee
Pluristem Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pluristem Ltd. filed Critical Pluristem Ltd.
Publication of WO2014141111A1 publication Critical patent/WO2014141111A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Definitions

  • GVHD graft-versus-host disease
  • histocompatible transplants to 60% - 70% in recipients of mismatched hematopoietic cells or hematopoietic cells from an unrelated donor.
  • Treatment strategies for acute GVHD aim to reduce the immune reaction to the donor T cells and therefore includes immunosuppressive treatment like cyclosporine, high dose steroids, and methotrexate.
  • the standard therapy for de novo acute GVHD is high dose methylprednisolone, with expected response rates of 18% - 50%.
  • expected survival is less than 30%. Therefore, novel therapies are urgently needed for this patient population.
  • graft-versus-host disease graft-versus-host disease
  • methods of treating, inhibiting, or preventing graft-versus-host disease (GVHD) in a subject in need thereof comprising administering to said subject a therapeutically or prophylactically effective amount of adherent stromal cells, thereby treating or preventing the GVHD.
  • GVHD graft-versus-host disease
  • adherent stromal cells for the manufacture of a medicament for treating or preventing GVHD in a subject, wherein the cells are optionally obtained from placental or adipose tissue.
  • adherent stromal cells for the treatment or prevention of GVHD, wherein the cells are optionally obtained from 3D culturing.
  • adherent stromal cells or compositions comprising adherent stromal cells wherein the cells are derived from placental or adipose tissue.
  • Embodiments of the disclosure further relate to articles of manufacture including a packaging material including a label for use in treating or preventing GVHD, wherein the packaging material packages a pharmaceutically effective amount of adherent stromal cells from a placenta or adipose tissue.
  • the adherent stromal cells are adherent stromal cells from placenta or adipose tissue, described in International Patent Publication Numbers WO 2007/108003 and WO 2009/037690 (3D-adherent cells by Plurix; PLX cells), each of which is incorporated herein by reference herein in its entirety.
  • the subject has acute GVHD.
  • the subject may have grade I acute GVHD under the Glucksberg GVHD grading system.
  • the subject with grade I acute GVHD is receiving one or more of a topical therapy for skin rash and a calcineurin inhibitor.
  • the subject has grade II- IV acute GVHD under the Glucksberg grading system. Subjects with grade II-IV acute GVHD may be receiving a corticosteroid.
  • the subject has chronic GVHD.
  • the subject with chronic GVHD may be receiving an immunosuppressive treatment.
  • the immunosuppressive treatment may be one or more of methotrexate, cyclosporine, a corticosteroid, and antithymocyte globulin.
  • the corticosteroid may be methylprednisolone.
  • the subject requires or has required immunosuppressive treatment for a period of one or more years.
  • the subject has steroid-refractory GVHD.
  • the subject may be receiving one or more of extracorporeal photophoresis, anti-TNF alpha antibody, mammalian target of rapamycin (mTOR) inhibitor, mycophenolate mofetil, interleukin-2 receptor antibody, alemtuzumab pentostatin, mesenchymal stem cells, and methotrexate.
  • mTOR mammalian target of rapamycin
  • mycophenolate mofetil mycophenolate mofetil
  • interleukin-2 receptor antibody alemtuzumab pentostatin
  • mesenchymal stem cells and methotrexate.
  • adherent cells are administered at multiple time points and/or at variable intervals. In some embodiments, the cells are administered in a single administration. In further embodiments, the cells are administered in multiple administrations. Cells may be administered with a dosage of from about 150 million to about 300 million cells. In some embodiments, subsequent doses are lower in cell number. The schedule of administration and/or dosing may be determined in consultation with an oncologist.
  • adherent stromal cells are administered to a subject systemically. In further embodiments, the cells are administered locally. The adherent cells may be administered locally at the site of a tissue transplant. In some embodiments, adherent cells are administered intramuscularly. Intramuscular (IM) administration also allows secretion of cytokines at systemically detectable levels, and offers ease and speed of delivery. In some embodiments, adherent stromal cells (including, for example, PLX cells) are administered by one or more further modes of administration, including, for example, intravenous, intraperitoneal, subcutaneous, intradermal, intraosseous infusion, and inhalation administration, and the like.
  • the subject receiving adherent stromal cells has received or will receive a hematopoietic stem cell transplant.
  • the subject has a hematopoietic neoplastic disorder.
  • the subject may have leukemia.
  • the leukemia may be chronic myelogeneous leukemia or chronic lymphocytic leukemia.
  • the subject has lymphoma.
  • the lymphoma may be Hodgkin's disease or non-Hodgkin's lymphoma.
  • the subject has multiple myeloma.
  • the subject may receive or will receive a bone marrow, peripheral blood stem cell, or cord blood transplant.
  • the subject has received or will receive whole body irradiation.
  • the subject is female.
  • the subject has received or will receive a transplant from an HLA-matched related donor or an HLA-matched unrelated donor.
  • the subject may also have received or may receive a transplant from an HLA-mismatched related or unrelated donor.
  • the adherent stromal cells may be obtained from a three-dimensional (3D) culture.
  • the three-dimensional (3D) culture may comprise a 3D bioreactor.
  • the adherent cells in the 3D culture are effected under perfusion. Culturing of the adherent cells may be effected for at least 3 days. Culturing may be effected until at least 10 % of the adherent cells are proliferating.
  • adherent cells comprise cells cultured from the placenta or adipose tissue under 2 dimensional (2D) culturing conditions.
  • adherent stromal cells including, for example, PLX cells
  • adherent stromal cells are autologous to the subject.
  • adherent stromal cells are allogeneic to the subject.
  • Figure 1 shows the percent body weight following irradiation and induction of GVHD for mice receiving PLX treatment via i.v. (triangle) and i.m (square) injection and controls (diamonds).
  • Figure 2 shows the percent survival and chimerism of mice following induction of GVHD and treatment.
  • Figure 2A shows the survival of mice receiving PLX cells via i.m.
  • Figure 2B shows the percent chimerism of mice in negative control group and mice receiving PLX cells via i.m. and i.v. injection.
  • Figure 3 shows the GVHD score following transplantation.
  • Figure 3 A shows the average GVHD score over a 35 day period for negative controls (diamonds) and mice receiving PLX cells via i.m. (squares) or i.v. (triangle) injection.
  • Figure 3B shows the median GVHD score for all three groups at Day 25 and Day 36 following transplantation.
  • Figure 4 shows the skin GVHD score following transplantation.
  • Figure 4A shows the average skin GVHD score over a 32 day period for negative controls (diamonds) and mice receiving PLX cells via i.m. (squares) or i.v. (triangle) injection.
  • Figure 4B shows the median skin GVHD score for all three groups at Day 32 following transplantation.
  • Figure 5 shows the GVHD score in surviving mice following transplantation.
  • Figure 5A shows the average GVHD score in surviving mice at day 45 following transplantation for negative controls (diamonds) and mice receiving PLX cells via i.m. (squares) or i.v. (triangle) injection.
  • Figure 5B shows the median GVHD score for surviving mice in all three groups at Day 36 and Day 43 following transplantation.
  • Figure 6 shows the fur loss associated with skin GVHD that occurred in several control mice and an IM PLX-treated mouse but not in normal mice or IV PLX-treated mice.
  • Ranges can be expressed herein as from “about” one particular value, and/or to
  • GVHD graft-versus-host disease
  • BM bone marrow
  • T-cells from the transplanted BM recognize the host (the bone marrow- transplanted patient i.e., the recipient) as non-self and attack its tissues and organs.
  • the patient's own immune system is suppressed prior to the transplant to prevent rejection of the graft and therefore cannot respond to the attack.
  • the organs most commonly attacked are the
  • GI gastrointestinal
  • the graft must contain immunologically competent cells.
  • the host must be immunologically distinct (i.e., histo-incompatible) from the graft, such that host antigens appear foreign to the immune cells of the graft and can therefore activate these cells.
  • the host itself must be incapable of mounting an effective immune response to the graft.
  • GVHD commonly develops after an allogeneic bone marrow transplant (BMT). But it can also appear after solid organ transplantation.
  • BMT bone marrow transplant
  • the exact incidence rate of GVHD after solid organ transplantation is unknown. Mild cases likely remain undiagnosed because the clinical features of fever, rash, and diarrhea can be misinterpreted as related to post- transplantation infections.
  • the incidence rate of GVHD is highest after small bowel
  • transplantation (about 5%), followed by liver transplantation. But in general, the incidence rate for solid organ transplantation is very small relative to bone marrow transplantation.
  • aspects of the disclosure further relate to a multifold mode of action for GVHD treatment, inhibition, or prophylaxis using adherent stromal cells, such as, for example, adherent stromal cells from placenta or adipose tissue, including, for example, PLX cells.
  • adherent stromal cells such as, for example, adherent stromal cells from placenta or adipose tissue, including, for example, PLX cells.
  • “Inhibit,” “inhibiting,” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
  • Treatment means a method of reducing the effects of a disease or condition.
  • Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms.
  • the treatment can be any reduction from native levels and can be but is not limited to the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, treatment” can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression.
  • a disclosed method for reducing the effects of GVHD is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject with GVHD when compared to native levels in the same subject or control subjects.
  • the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
  • treatment does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition (e.g.., GVHD).
  • treatment can not only refer to the ablation of the disease state, but the reversal of the condition. It is also understood that by correcting or improving symptoms associated with GVHD, the disease state of GVHD is being treated.
  • prevention refers to any methodology where the disease state does not occur due to the actions of the methodology (such as, for example, administration of adherent stromal cells). In one aspect, it is understood that prevention can also mean that the disease is not established to the extent that occurs in untreated controls. For example, there can be a 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, or 100% reduction in the establishment of disease.
  • Adherent stromal cells are cells obtained from a tissue, including but not limited to placenta and adipose tissue, that are adherent when cultured in vitro, typically express (i.e., have positive surface marker expression ) one or more, two or more, three or more, or all four of CD105, CD73, CD90 and CD29 and lack detectable expression (i.e., have negative surface marker expression) of at least one, two , three, four, five, six, seven, eight, nine, or all ten of CD3, CD4, CD45, CD80, HLA-DR, CD1 lb, CD14, CD19, CD34 and CD79 by flow cytometry compared to an isotype control.
  • ASC Adherent stromal cells
  • placenta refers to any portion of the mammalian female organ which lines the uterine wall and during pregnancy envelopes the fetus, to which it is attached by the umbilical cord. Following birth, the placenta is expelled (and is referred to as a post-partum placenta). In some embodiments, "placenta” refers to whole placenta.
  • the placental-derived ASCs may be obtained from both fetal (i.e., amnion or inner parts of the placenta) and maternal (i.e., decidua basalis, and decidua parietalis) parts of the placenta unless the context otherwise makes clear that only fetal or maternal parts are meant.
  • adherent stromal cells including, for example, PLX cells
  • compositions comprising said adherent stromal cells (including, for example, PLX cells), or medicaments manufactured using said adherent stromal cells (including, for example, PLX cells) in performing the methods of treatment, inhibition, or prevention of GVHD disclosed herein.
  • the disclosed adherent stromal cells, medicaments, and/or compositions can be administered singly or in multiple administrations.
  • a method of treating, inhibiting, or preventing GVHD and uses comprising administering the disclosed adherent stromal cells (including, for example, PLX cells), medicaments, and/or compositions comprising said cells, wherein the adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells are administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 24, 25, 30, 35, 36, 40, 45, 48, 50, 55, 60 or more times.
  • the adherent stromal cells or compositions comprising said cells may be administered at regular or variable intervals.
  • adherent stromal cells including, for example, PLX cells
  • compositions comprising said cells may be administered regularly such that they or administered hourly, every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours; daily, every other day; every third day, weekly, every two weeks, monthly, or yearly.
  • cells or compositions comprising said cells can be administered according to the methods at irregular (i.e., variable intervals) such as, for example, a first dose, a second dose a week later, and a third dose a month following the first dose later; or a first dose followed by a second dose a month later and a third dose three months following the first dose; or doses at one week intervals for three months, followed by monthly intervals until the one year point, followed by yearly doses.
  • irregular i.e., variable intervals
  • adherent stromal cells compositions comprising adherent stromal cells, and/or medicaments manufactured using said adherent stromal cells concluding, for example, PLX cells
  • an adherent stromal cells compositions comprising adherent stromal cells, and/or medicaments manufactured using said adherent stromal cells concluding, for example, PLX cells
  • the disclosed adherent stromal cells including, for example, PLX cells
  • medicaments including, for example, PLX cells
  • compositions comprising adherent stromal cells can be administered before (prophylactically), after (therapeutically), concurrently with adherent stromal cells
  • the disclosed adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered 7, 6, 5, 4, 3, 2, days, 24, 23, 22, 21, 20, 19, , 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 hours, 45, 30, 15, 10, 5, 4, 3, 2, or 1 min or any combination thereof, before administration of the graft in the disclosed methods and uses of treating GVHD.
  • the disclosed adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60min, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 20, 24, 25, 30, 36, 40, 45, 48, 50, 55, or 60 hours, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months or any combination thereof after administration of the graft in the disclosed methods and uses of treating GVHD.
  • adherent stromal cells including, for example, PLX cells
  • compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered after onset of GVHD.
  • methods of treating GVHD wherein the adherent stromal cells, or medicament manufactured using said adherent stromal cells are administered 1, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60min, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 20, 24, 25, 30, 36, 40, 45, 48, 50, 55, or 60 hours, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months or any combination thereof after onset of GVHD.
  • adherent stromal cells including, for example, PLX cells
  • compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered in combination before, concurrently with, and/or after administration of the graft in the disclosed methods and uses of treating GVHD.
  • GVHD vascular endothelial growth factor
  • methods for treating, inhibiting, or preventing GVHD in a subject in need thereof comprising administering to the subject adherent stromal cells, medicaments manufactured using said adherent stromal cells, and/or composition comprising adherent stromal cells, wherein the method further comprises an immunosuppressive agent, steroid, anti-inflammatory, small molecule, pharmaceutical, antibody, or other agent.
  • a topical therapy for skin rash; a calcineurin inhibitor; a corticosteroid; immunosuppressive treatment e.g., methotrexate, cyclosporine, a corticosteroid, and/or anti- thymocyte globulin
  • immunosuppressive treatment e.g., methotrexate, cyclosporine, a corticosteroid, and/or anti- thymocyte globulin
  • anti-TNF alpha antibody e.g., methotrexate, cyclosporine, a corticosteroid, and/or anti- thymocyte globulin
  • anti-TNF alpha antibody e.g., methotrexate, cyclosporine, a corticosteroid, and/or anti- thymocyte globulin
  • anti-TNF alpha antibody e.g., methotrexate, cyclosporine, a corticosteroid, and/
  • the decision of additional agents to be administered in addition to the adherent stromal cells (including, for example, PLX cells), medicament, or compositions in the disclosed methods is determined based on whether the subject has acute or chronic GVHD and/or the grade of GVHD. Accordingly, disclosed herein are methods of treating, inhibiting, or preventing GVHD in a subject comprising administering to the subject adherent stromal cells, compositions comprising said adherent stromal cells, or medicaments manufactured using said stromal cells, wherein the subject has acute GVHD.
  • GVHD GVHD-in-viral graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft graft
  • GVHD can be mild, moderate, or severe, depending on the extent of damage inflicted to different organs.
  • the disease is divided into acute and chronic GVHD according to clinical manifestations.
  • Patients with acute GVHD typically suffer damage to the skin, GI tract, and liver. Skin damage ranges from redness to exfoliation. Insult to the GI tract can result in bloody diarrhea and blood loss. Liver manifestations, though usually cholestatic in nature, can include liver failure in rare cases.
  • Acute GVHD usually develops within the first 100 days after transplantation, but it can also occur later.
  • the clinical manifestations of chronic GVHD include red and itchy skin, dry eyes, dry mouth, abnormal liver function with jaundice, and lung damage due to
  • Chronic GVHD is the major cause of non-relapse mortality after allogeneic hematopoietic transplantations. Chronic GVHD usually develops more than 100 days after transplantation, but it can appear sooner.
  • Chronic GVHD patients with chronic GVHD require prolonged immunosupressive treatment, averaging two to three years in length.
  • the mechanisms underlying chronic GVHD are considered to be somewhat distinct from those of acute GVHD.
  • chronic GVHD is not simply an end-stage of acute GVHD.
  • the acute GVHD stage for each target organ is first determined according to certain clinical measures, as provided below in Table I.
  • Stage is downgraded by one stage if an additional cause of hyperbilirubinemia is documented.
  • the overall acute GVHD grade is then determined using either the IBMTR or Glucksgerg systems, as shown in tables II and II below.
  • stage 1 liver or gut, up to stage 3
  • disclosed herein are methods of treating, inhibiting, or preventing GVHD, adherent stromal cells for use in manufacturing a medicament for treating, inhibiting, or preventing GVHD, or adherent stromal cells or compositions comprising said adherent stromal cells wherein the subject with GVHD or receiving the medicament, adherent stromal cells, or compositions comprising adherent cells has been exposed, is being exposed, or will be exposed to whole body irradiation.
  • disclosed herein are methods of treating, inhibiting, or preventing GVHD, adherent stromal cells for use in manufacturing a medicament for treating, inhibiting, or preventing GVHD, or adherent stromal cells or compositions comprising said adherent stromal cells wherein the subject with GVHD or receiving the medicament, adherent stromal cells, or compositions comprising adherent cells is female, disclosed herein are methods of treating, inhibiting, or preventing GVHD, adherent stromal cells for use in manufacturing a medicament for treating, inhibiting, or preventing GVHD, or adherent stromal cells or compositions comprising said adherent stromal cells (including, for example, PLX cells) wherein the subject with GVHD or receiving the medicament, adherent stromal cells, or compositions comprising adherent cells will receive, is concurrently receiving, or will receive a hematopoietic stem cell, bone marrow, peripheral stem cell, or cord blood transplant.
  • the risk of GVHD can be lowered by reducing the intensity of the conditioning regimen, by excluding T cells from graft (which reduces graft- versus-leukemia [GVL] and increase the recurrence of malignancy), or by administering immunosuppressive treatment such as methotrexate, cyclosporine, corticosteroids, or anti-thymocyte globulin.
  • immunosuppressive treatment such as methotrexate, cyclosporine, corticosteroids, or anti-thymocyte globulin.
  • steroid- refractory acute GVHD extracorporeal photopheresis, anti-tumour necrosis factor a antibodies, mammalian target of rapamycin (mTOR) inhibitors, mycophenolate mofetil, interleukin-2 receptor antibodies.
  • mTOR mammalian target of rapamycin
  • mycophenolate mofetil mycophenolate mofetil
  • interleukin-2 receptor antibodies interleukin-2 receptor antibodies.
  • third line treatment options in acute steroid-refractory GVHD alemtuzumab pentostatin, mesenchymal stem cells and methotrexate.
  • the method can further comprise administering to the subject extracorporeal photopheresis, anti- tumour necrosis factor a antibodies, mammalian target of rapamycin (mTOR) inhibitors, mycophenolate mofetil, interleukin-2 receptor antibodies, alemtuzumab pentostatin,
  • mTOR mammalian target of rapamycin
  • mycophenolate mofetil mycophenolate mofetil
  • interleukin-2 receptor antibodies alemtuzumab pentostatin
  • mesenchymal stem cells mesenchymal stem cells, methotrexate, or any combination thereof.
  • Rituximab tyrosine kinase inhibitors
  • chemotherapeutic drugs e.g. Pentostatin
  • T and B cell inhibitors e.g. Mycofenolate
  • disclosed herein are methods of treating, inhibiting, or preventing GVHD, wherein the subject has grade I acute GVHD under the Glucksberg grading system. Where the subject has grade I acute GVHD, disclosed are methods of treating, inhibiting, or preventing GVHD in a subject comprising administering to the subject adherent stromal cells, compositions comprising adherent stromal cells, and/or medicaments
  • disclosed herein are methods of treating, inhibiting, or preventing GVHD, wherein the subject has grade II- IV acute GVHD under the Glucksberg grading system. Where the subject has grade II- IV acute GVHD, disclosed are methods of treating, inhibiting, or preventing GVHD in a subject comprising administering to the subject adherent stromal cells, compositions comprising adherent stromal cells, and/or medicaments manufactured using adherent stromal cells further comprising administering to the subject a corticosteroid.
  • disclosed herein are methods of treating, inhibiting, or preventing GVHD, wherein the subject has chronic GVHD.
  • methods of treating, inhibiting, or preventing GVHD in a subject comprising administering to the subject adherent stromal cells (including, for example, PLX cells), compositions comprising adherent stromal cells, and/or medicaments manufactured using adherent stromal cells further comprising administering to the subject an immunosuppressive treatment, such as, for example, methotrexate, cyclosporine, a corticosteroid, and anti-thymocyte globulin.
  • adherent stromal cells including, for example, PLX cells
  • compositions comprising adherent stromal cells, and/or medicaments manufactured using adherent stromal cells further comprising administering to the subject an immunosuppressive treatment, such as, for example, methotrexate, cyclosporine, a corticosteroid, and anti-thymocyte globulin.
  • MSCs Mesenchymal stem cells possess immunomodulatory and anti-inflammatory properties that may make them an effective therapy for acute and possibly also chronic GVHD.
  • challenges include a requirement for HLA matching in some cases, the difficulty in obtaining bone-marrow-derived MSCs, and the need to culture the cells to obtain higher cell numbers.
  • Three-dimensionally-adherent cells from bone marrow, placenta, and adipose tissues have immunomodulatory and anti-inflammatory capabilities mediated by the secretion of a number of cytokines and chemokines.
  • PLX cells have the potential of ameliorating or preventing GVHD.
  • PLX cells have a limited differentiation capacity and therefore are not MSCs, which is preferred for GVHD.
  • PLX cells do not require HLA matching, are derived from an abundant source, and can be cultured in large numbers and at a low cost.
  • methods of treating, inhibiting, or preventing GVHD in a subject comprising administering to the subject adherent stromal cells, a medicament manufactured using said adherent stromal cells, and/or compositions comprising said adherent stromal cells wherein the recipient is an HLA- matched related recipient; an HLA-matched unrelated recipient, or an HLA-mismatched recipient.
  • the source of the adherent stromal cells are an HLA matched related donor, HLA matched unrelated donor, or an HLA-mismatched donor, respectively.
  • tissue being grafted in a recipient in the disclosed methods of treating, inhibiting, or preventing GVHD may be from an autologous, syngeneic, allogeneic, or non-autologous source.
  • adherent stromal cells for the treatment, inhibition, or prevention of GVHD or for use in the manufacture of a medicament for the treatment, inhibition, or prevention of GVHD, as well as, compositions comprising said cells. It is understood and herein contemplated that the disclosed adherent stromal cells can be obtained from any source including but not limited to adipose tissue, placental tissue, and bone marrow. 65. It is further contemplated herein that the adherent stromal cells for use in
  • a medicament as part of a composition, and/or in the method of treating, inhibiting, or preventing GVHD disclosed herein can be propagated using two dimensional ("2D") or three dimensional ("3D") culturing conditions.
  • 2D two dimensional
  • 3D three dimensional
  • adherent stromal cells e.g., placental or adipose stromal cells
  • uses in manufacturing a medicament e.g., placental or adipose stromal cells
  • the adherent stromal cells e.g., placental or adipose stromal cells
  • adherent stromal cells e.g., placental or adipose stromal cells
  • uses in manufacturing a medicament and/or methods of treating, inhibiting, or preventing GVHD
  • adherent stromal cells e.g., placental or adipose stromal cells
  • 3D culturing conditions including, example in a 3D bioreactor
  • Two-dimensional refers to a culture in which the cells are grown on a flat tissue culture plate surface (e.g. "TCPS").
  • 3D three dimensional
  • 3D surfaces include but are not limited to porous materials, woven fibers, non-woven fibers, hollow fibers, surfaces with nano or micron scale roughness, sponges, and microcarriers. Other examples of 3D surfaces are given in the examples. It will be appreciated that the conditions of the three-dimensional culture are such that they enable expansion of the adherent cells.
  • ASC-2D means a culture of adherent stromal cells from any tissue source that have been grown in 2D culture conditions without a period of 3D culture.
  • ASC-3D means a culture of adherent stromal cells from any tissue source that have been grown in 3D-culture conditions. This term encompasses cells that are grown initially in 2D culture then moved to a 3D culture.
  • Protacental ASC-2D as used herein is a general term for any culture of placental- derived adherent stromal cells produced using a 2D culture system.
  • Proliferative ASC-3D as used herein is a general term for any culture of placental- derived adherent stromal cells produced using a 3D culture system.
  • expanding and expansion refer to an increase of a cell population (e.g. , at least 2 fold), optionally without differentiation accompanying such increase.
  • the cells may be of autologous or non-autologous source (i.e., allogeneic or xenogeneic) of fresh or frozen (e.g., cryo-preserved) preparations.
  • the subject may be administered with additional chemical drugs (e.g., immunomodulatory, chemotherapy etc.) or cells.
  • the donor source adherent stromal cells does not have to be HLA-matched with the recipient. Accordingly, disclosed herein are adherent stromal cells, medicaments manufactured using said cells, and compositions comprising said cells wherein the recipient is an HLA-matched related recipient; an HLA- matched unrelated recipient, or an HLA-mismatched recipient.
  • the source of the adherent stromal cells are an HLA matched related donor, HLA matched unrelated donor, or an HLA-mismatched donor, respectively.
  • tissue being grafted in a recipient may be from a non-autologous source.
  • non-autologous cells may induce an immune reaction when administered to the body
  • approaches have been developed to reduce the likelihood of rejection of non-autologous cells. These include either suppressing the recipient immune system or encapsulating the non-autologous cells in immunoisolating, semipermeable membranes before transplantation.
  • Encapsulation techniques are generally classified as microencapsulation, involving small spherical vehicles and macroencapsulation, involving larger flat-sheet and hollow-fiber membranes (Uludag, H. et al. Technology of mammalian cell encapsulation. Adv Drug Deliv Rev. 2000; 42: 29-64).
  • microcapsules Methods of preparing microcapsules are known in the arts and include for example those disclosed by Lu MZ, et al., Cell encapsulation with alginate and alpha- phenoxycinnamylidene-acetylated poly(allylamine). Biotechnol Bioeng. 2000, 70: 479-83, Chang TM and Prakash S. Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms. Mol Biotechnol. 2001, 17: 249-60, and Lu MZ, et al., A novel cell encapsulation method using photosensitive poly(allylamine alpha-cyanocinnamylideneacetate). J Microencapsul. 2000, 17: 245-51.
  • microcapsules are prepared by complexing modified collagen with a ter-polymer shell of 2-hydroxyethyl methylacrylate (HEM A), methacrylic acid (MA A) and methyl methacrylate (MMA), resulting in a capsule thickness of 2-5 ⁇ .
  • HEM A 2-hydroxyethyl methylacrylate
  • MA A methacrylic acid
  • MMA methyl methacrylate
  • Such microcapsules can be further encapsulated with additional 2-5 ⁇ ter-polymer shells in order to impart a negatively charged smooth surface and to minimize plasma protein absorption (Chia, S.M. et al. Multi-layered microcapsules for cell encapsulation Biomaterials. 2002 23: 849-56).
  • microcapsules are based on alginate, a marine polysaccharide (Sambanis, A. Encapsulated islets in diabetes treatment. Diabetes Technol. Ther. 2003, 5: 665-8) or its derivatives.
  • microcapsules can be prepared by the polyelectrolyte complexation between the polyanions sodium alginate and sodium cellulose sulphate with the polycation poly(methylene-co-guanidine) hydrochloride in the presence of calcium chloride.
  • the cells can be administered either per se or, preferably as a part of a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier. Also, as noted above, the cells can be placental-derived, thus, the
  • compositions and pharmaceutical compositions for use in any of the various methods can be placental-derived adherent stromal cells.
  • the placental-derived ASC may be ASC-3D or ASC- 2D.
  • adherent stromal cells disclosed in this paper have many utilities associated with the treatment, inhibition, or prevention of GVHD, including, but not limited to a direct use in treatment, inhibition, or prevention of GVHD or in the preparation or manufacture of a medicament for treating, inhibiting, or preventing GVD. Accordingly, in one aspect, disclosed herein is the use of adherent stromal cells for the manufacture of a medicament for treating or preventing GVHD in a subject. It is understood that such adherent stromal cells can be obtained from placental or adipose tissue.
  • ASC-2D cells When ASC-2D cells are used herein, they may be produced by any process using a 2D culture system, such as flasks or plates. In general, cells are seeded into a 2D vessel and allowed to adhere. The first passage is usually carried out after 10-15 days. Beginning at passage 2 and continuing until passage 6-8, cells are passaged when the culture reached 70-80 % confluence, usually after about 3-5 days (1.5-2 doublings). The cells are detached from plates or flasks using 0.25 % trypsin-EDTA (4 minutes at 37 °C) and seeded in a culture density of about 3 + 0.2 x 10 3 cells/cm 2 . The size of the tissue culture flasks or plates can be increased as the passaging proceeds.
  • the culturing process may start in an 80 cm 2 tissue culture flask, continue in 175 cm 2 , and then in 500 cm 2 (Triple flask).
  • cells may be re-seeded into Cell Factory 10 tray (6320 cm2).
  • ASC-2D are generally detached from the culture surface with Trypsin-EDTA
  • the ASC-2D are placental-derived ASC-2D.
  • adherent stromal cells in one aspect, disclosed herein are adherent stromal cells, medicaments manufactured from said adherent stromal cells, and/or compositions comprising adherent stromal cell wherein the adherent stromal cells are derived from placental MSC.
  • adherent stromal cells compositions comprising said adherent stromal cells, and/or medicament manufactured with said adherent stromal cells wherein the adherent stromal cells are obtained from a three-dimensional culture (3D) such as a culture in a 3D bioreactor, such as, for example, PluriXTM Plug Flow bioreactor (Pluristem, Haifa, Israel); CelligenTM Plug Flow bioreactor; or Packed Bed Spinner Vessel. Said culturing methods can be effected under perfusion. It is further contemplated herein that the adherent cells can be cultured for at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 hours, 1, 2, 3, 4, 5, 6, 7 days, 2, 3, 4, weeks, 2 or 3 months.
  • 3D three-dimensional culture
  • the adherent cells can be cultured for at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 hours, 1, 2, 3, 4, 5, 6, 7 days, 2, 3, 4, weeks,
  • Non-limiting examples of base media useful in culturing cells to derive ASCs include Minimum Essential Medium Eagle, ADC-1, LPM (Bovine Serum Albumin-free), FIO(HAM), F12 (HAM), DCCM1, DCCM2, RPMI 1640, BGJ Medium (with and without Fitton-Jackson Modification), Basal Medium Eagle (BME-with the addition of Earle's salt base), Dulbecco's Modified Eagle Medium (DMEM- without serum), Yamane, IMEM-20, Glasgow Modification Eagle Medium (GMEM), Leibovitz L-15 Medium, McCoy's 5A Medium, Medium M199 (M199E-with Earle's sale base), Medium Ml 99 (M199H-with Hank's salt base), Minimum Essential Medium Eagle (MEM-E-with Earle's salt base), Minimum Essential Medium Eagle (MEM-H-with Hank's salt base), Minimum Essential Medium Eagle (MEM-H-with Hank's salt base), Minimum Essential Medium Eagle (MEM-H-
  • the medium may be supplemented such as with serum such as fetal serum of bovine or other species, and optionally or alternatively, growth factors, vitamins (e.g. ascorbic acid), cytokines, salts (e.g. B-glycerophosphate), steroids (e.g.
  • dexamethasone and hormones e.g., growth hormone, erythropoeitin, thrombopoietin, interleukin 3, interleukin 6, interleukin 7, macrophage colony stimulating factor, c-kit ligand/stem cell factor, osteoprotegerin ligand, insulin, insulin like growth factors, epidermal growth factor, fibroblast growth factor, nerve growth factor, cilary neurotrophic factor, platelet derived growth factor, and bone
  • hormones e.g., growth hormone, erythropoeitin, thrombopoietin, interleukin 3, interleukin 6, interleukin 7, macrophage colony stimulating factor, c-kit ligand/stem cell factor, osteoprotegerin ligand, insulin, insulin like growth factors, epidermal growth factor, fibroblast growth factor, nerve growth factor, cilary neurotrophic factor, platelet derived growth factor, and bone
  • morphogenetic protein at concentrations of between picogram/ml to milligram/ml levels.
  • Such components can be antibiotics, antimycotics, albumin, amino acids, and other components known to the art for the culture of cells.
  • adherent materials that may be used to culture cells as described herein include, but are not limited to, a polyester, a polypropylene, a polyalkylene, a
  • polyfluorochloroethylene a polyvinyl chloride, a polystyrene, a polysulfone, a cellulose acetate, a glass fiber, a ceramic particle, a matrigel, an extra cellular matrix component (e.g., fibronectin, chondronectin, laminin), a collagen, a hydro gel, a poly L lactic acid and an inert metal fiber.
  • any of a variety of culture methods including but not limited to suspension bioreactors, packed bed bioreactors, fixed bed bioreactors, rolling flasks, and any method of culturing cells in a liquid environment, may be used in the various aspects and embodiments of the disclosure.
  • Adherent material for the 3D aspect of the present disclosure is configured for 3D culturing thereby providing a growth matrix that substantially increases the available attachment surface for the adherence of the stromal cells so as to mimic the infrastructure of the tissue (e.g., placenta).
  • the increase is by a factor of at least from 5 to 30 times, calculated by projection onto a base of the growth matrix.
  • Such an increase by a factor of about 5 to 30 times is per unit layer, and if a plurality of such layers, either stacked or separated by spacers or the like, is used, the factor of 5 to 30 times applies per each such structure.
  • the matrix is used in sheet form, preferably non-woven fiber sheets, or sheets of open-pore foamed polymers, the preferred thickness of the sheet is about 50 to 1000 ⁇ or more, there being provided adequate porosity for cell entrance, entrance of nutrients and for removal of waste products from the sheet.
  • the pores have an effective diameter of 10 ⁇ to 300 ⁇ .
  • Such sheets can be prepared from fibers of various thicknesses, in one embodiment the fiber thickness or fiber diameter range is from about 0.5 ⁇ to 100 ⁇ , in other embodiments it is in the range of 10 ⁇ to 15 ⁇ in diameter.
  • the structures of the 3D culture system may be supported by, or even better bonded to, a porous support sheet or screen providing for dimensional stability and physical strength.
  • a porous support sheet or screen providing for dimensional stability and physical strength.
  • Such matrix sheets may also be cut, punched, or shredded to provide particles with projected area of the order of about 0.2 mm 2 to about 10 mm 2 , with the same order of thickness (about 50 to 1000 ⁇ ). Further details relating to the fabrication, use and/or advantages of the growth matrix which was used to reduce the present disclosure to practice are described in U.S. Pat. No. 5,168,085, and in particular, U.S. Pat. No. 5,266,476, both of which are incorporated herein by reference.
  • the adherent surface which comprises the 3D structure may be of any shape, including but not limited to squares, triangles, rings, disks, balls, ovals, cruciforms and any other shape that can be formed by a flexible or inflexible 3D structure.
  • culturing is preferably effected in a 3D bioreactor.
  • bioreactors include, but are not limited to, a plug flow bioreactor, a continuous stirred tank bioreactor and a stationary-bed bioreactor.
  • An example of a three dimensional (3D) plug flow bioreactor is described in U.S. Pat. No. 6,911,201 that is capable of supporting the growth and prolonged maintenance of stromal cells.
  • stromal cells are seeded on porous carriers made of a non-woven fabric matrix of polyester, packed in a glass column, thereby enabling the propagation of large cell numbers in a relatively small volume.
  • the matrix used in the plug flow bioreactor can include, but is not limited to, sheet form, non-woven fiber sheets, or sheets of open-pore foamed polymers, the preferred thickness of the sheet is about 50 to 1000 ⁇ or more, there being provided adequate porosity for cell entrance, entrance of nutrients and for removal of waste products from the sheet.
  • 3D bioreactors include, but are not limited to, a plug flow bioreactor, a continuous stirred tank bioreactor, a stationary-bed bioreactor, a CELLIGEN PLUS® bioreactor system (New Brunswick Scientific (NBS), and a BIOFLO 310 bioreactor system (New Brunswick Scientific (NBS).
  • Other examples of bioreactors include an air-lift bioreactor where air is typically fed into the bottom of a central draught tube flowing up while forming bubbles; a cell seeding perfusion bioreactor with Polyactive foams [as described in Wendt, D.
  • tubular poly-L-lactic acid (PLLA) porous scaffolds in a radial-flow perfusion bioreactor [as described in Kitagawa et al.,
  • bioreactors are capable of 3D expansion of adherent cells under controlled conditions (e.g., pH, temperature and oxygen levels) and with constant cell growth medium perfusion. Furthermore, the cell cultures can be directly monitored for concentration levels of glucose, lactate, glutamine, glutamate and ammonium. The glucose consumption rate and the lactate formation rate of the adherent cells enable to measure cell growth rate and to determine the harvest time.
  • Cell seeding is preferably effected at a concentration of 20,000-1,500,000 cells / ml at seeding. In an exemplary embodiment a total of 150 + 30 x 10 6 cells are seeded, 3-5 x 10 6 cell/g carrier are seeded, or 0.015-0.1 x 10 6 cell/ml are seeded.
  • Cells can be harvested when at least about 10% of cells are proliferating while avoiding uncontrolled differentiation and senescence.
  • methods of treating, inhibiting, and or preventing GVHD wherein the adherent stromal cells, compositions comprising said cells, and/or medicaments manufactured using said cells wherein culturing of the adherent cells is effected until at least about 10% of the adherent cells are proliferating.
  • Culturing of adherent cells in the disclosed methods of treating, inhibiting, or preventing GVHD or uses for manufacture of a medicament can be effected for at least about 2 days, 3 days, 4 days, 5 days, 10 days, 20 days, a month or even more. It will be appreciated that culturing in a bioreactor can prolong this period.
  • Adherent cells of some embodiments of the present disclosure comprise at least about 10%, 28%, 30%, 50%, 80% or more proliferative cells (as can be assayed by FACS monitoring S and G2/M phases).
  • 2D cell medium (2D-Medium comprising DMEM supplemented with 10 % FBS, fungizone 0.25 ⁇ g/ml and gentamycine 50 ⁇ g/ml) is added and the digested tissue is roughly filtered through a sterile metal strainer, collected in a sterile beaker and centrifuged (10 minutes, 1200 RPM, 4 °C). Using gentle pipeting, suspended cells are then washed with 2D- Medium supplemented with antibiotics, seeded in 80 cm2 flasks and incubated at 37°C in a tissue culture incubator under humidified condition supplemented with 5 % C02. Following 2-3 days, in which the cells were allowed to adhere to the flask surface, they are washed with PBS and 2D-Medium was added.
  • 2D-Medium comprising DMEM supplemented with 10 % FBS, fungizone 0.25 ⁇ g/ml and gentamycine 50 ⁇ g/ml
  • placenta is one source of ASC and is the ASC source used in the
  • placenta is an exemplary source and other cells sources may be used.
  • ASC sources include adipose tissue, umbilical cord, blood, and bone marrow.
  • the ASC are not limited to placenta-derived ASC.
  • the ASC-2D, the ASC-3D, or both the ASC-2D and ASC- 3D are placenta-derived ASC.
  • the ASC-3D cells are produced using a PluriXTM Plug Flow bioreactor (Pluristem, Haifa, Israel) as illustrated in U.S. Pat. No. 6,911,201.
  • PluriXTM Plug Flow bioreactor is loaded with 1-100 ml packed 3D porous carriers (4 mm in diameter) made of a non- woven fabric matrix of polyester. These carriers enable the
  • the bioreactor is maintained in an incubator of 37°C, with flow rate regulated and monitored by a valve, and peristaltic pump.
  • the 02 proportion is suited to the level of dissolved 02 at the bioreactor exit, determined by a monitor.
  • Non-confluent primary human adherent 2D cell cultures are trypsinized, washed, resuspended in DMEM supplemented with 10% FBS, Pen-Strep-Nystatin mixture and 2 mM L- glutamine, and seeded (10 3 -10 5 cells/ml) via an injection point onto the 3D carriers in a sterile Plug Flow bioreactor.
  • PBS-Ca— Mg Biological Industries, Beit Ha'emek, Israel
  • Circulation medium is replaced with fresh DMEM media, every 4 hr to 7 days.
  • the total medium volume is removed from the bioreactor and bioreactor and carriers are washed 3-5 times with PBS.
  • PluriXTM 3D-adherent cells are then detached from the carriers with Trypsin-EDTA; (Biological Industries, Beit Ha'emek, Israel; 3-15 minutes with gentle agitation, 1-5 times), and are thereafter resuspended in DMEM and either used directly for testing or other uses or cryopreserved for later testing or use.
  • the PluriXTM ASC-3D are placental-derived ASC-3D.
  • the ASC-3D cells are produced using a CelligenTM Plug Flow bioreactor, as illustrated in US 2010/0209403 and WO 2009/037690.
  • the 3D growth phase is performed using an automatic CelliGen Plus® or BIOFLO 310 bioreactor system [(New Brunswick Scientific (NBS)] depicted in Figure 8C of US
  • the parameters of the process are monitored and controlled by a control console which included connectors for probes, motor and pumps, control loops for Dissolved Oxygen (DO), pH, perfusion and agitation (with a motor), a gases control system, water circulation and heating system for temperature control and an operator interface.
  • the controlled process parameters (such as temperature, pH, DO etc.) can be displayed on the operator interface and monitored by a designated controller.
  • the bioreactor generally contains 30-50 gr carriers
  • FIBRACEL® disks, NBS made of Polyester and Polypropylene and 1.5 + 0.1 L 3D-Medium.
  • the growth medium in the bioreactor is kept at the following conditions: 37 °C, 70 % Dissolved Oxygen (DO) and pH 7.3.
  • Filtered gases Air, C02, N2 and 02
  • RPM Rounds Per Minute
  • the cells are grown in a batch mode. Perfusion is initiated when the medium glucose concentration decreases below 550 mg/liter.
  • the perfusion is adjusted in order to keep the glucose concentration constant at approximately 550 + 50 mgUiter.
  • the glucose consumption rate and the lactate formation rate of the cell culture enables measure of the cell growth rate. These parameters are used to determine the harvest time based on accumulated experimental data.
  • the cell harvest process starts at the end of the growth phase (usually 4-10 days).
  • the 3D-grown culture is usually harvested by emptying the bioreactor vessel using gravitation via tubing to a waste container.
  • the vessel is opened and the carriers aseptically transferred from the basket to the upper basket net.
  • the bioreactor vessel is then closed and refilled with pre-warmed PBS (37°C).
  • the agitation speed is increased to about 150 RPM for 2 minutes.
  • the PBS is then drained and this washing procedure repeated twice.
  • Trypsin-EDTA (Trypsin 0.25 %, EDTA 1 mM) is added to the bioreactor vessel and carriers are agitated for 5 minutes in 150 RPM, 37 °C.
  • the cell suspension is collected to a sterile container containing 250 ml FBS.
  • the cell suspension (“PLX-C”) is then divided or further processed as needed for testing and use.
  • the CelligenTM ASC-3D are placental-derived ASC-3D.
  • the ASC-3D cells are produced using a packed bed spinner flask.
  • the packed is based on a 500ml glass spinner flask with a magnetic stirrer.
  • the spinner flask if fitted with a packed bed apparatus similar to the CelligenTM Plug Flow bioreactor (see above) which is packed with 1.8gr of FIBRACEL (or other carriers).
  • the spinner is batch fed (rather than by perfusion), fitted with two 0.22 ⁇ filters, and placed in a 37°c 5% C02 incubator.
  • Cells are seeded onto the scaffold by introducing to the medium and allowing 4 hours of 40 RPM agitation. Subsequently the RPM is increased to 120 RPM.
  • Medium is assessed daily for glucose level and replaced to maintain acceptable glucose concentration.
  • carriers are removed from the packed bed, washed twice with PBS, and processed or removed from the carriers by agitation and enzymatic digestion for further use.
  • compositions can also be administered in vivo in a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
  • the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art. 117.
  • the adherent stromal cells, medicaments manufactured using said adherent stromal cells, and/or compositions comprising said adherent stromal cells may be administered systemically or locally (including, for example, at the site of tissue transplantation or site of GVHD damage) in the disclosed methods of treating, inhibiting, and/or preventing GVHD disclosed herein.
  • the adherent stromal cells, medicaments, and/or compositions can be administered by any route suitable for the delivery of adherent stromal cells, medicaments, and/or composition comprising adherent stromal cells in the disclosed methods of treating, inhibiting, or preventing GVHD including, but not limited to orally, sublingually, rectally, parentally (e.g., intravenous injection (i.v.), intracranial injection (i.e.); intramuscular injection (i.m.), intraperitoneal injection (i.p.), and subcutaneous injection (s.c.) and intraosseous infusion (i.o.)), transdermally, extracorporeally, inhalation, topically or the like, including topical intranasal administration or administration by inhalant.
  • parentally e.g., intravenous injection (i.v.), intracranial injection (i.e.); intramuscular injection (i.m.), intraperitoneal injection (i.p.), and subcutaneous injection (s.c.) and
  • topical intranasal administration means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the composition through use of a nebulizer or like device.
  • Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. Oral delivery can be through pill, tablet, liquid, or sublingual droplets. Topical administration can be through ointment, gel, hydrogel, paste, film, cream, lotion, transdermal patch, dermal patch, shampoo, or liposomes.
  • the exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
  • Parenteral administration of the composition is generally characterized by injection.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions.
  • a more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein.
  • the materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands.
  • the following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, K.D., Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog.
  • Vehicles such as "stealth” and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells in vivo.
  • stealth and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells in vivo.
  • the following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214- 6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104: 179-187, (1992)).
  • receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes.
  • the internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation.
  • receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).
  • compositions including antibodies, can be used therapeutically in combination with a pharmaceutically acceptable carrier or excipient.
  • Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995.
  • an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic.
  • the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution.
  • the pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5.
  • Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.
  • compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.
  • compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.
  • compositions may also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.
  • the pharmaceutical composition may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated.
  • Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection.
  • the disclosed antibodies can be administered intravenously,
  • intraperitoneally intramuscularly, subcutaneously, intracavity, or transdermally.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.. 128.
  • compositions may potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
  • organic acids such as formic acid, acetic acid, propionic acid, glyco
  • Effective dosages and schedules for administering the compositions may be determined empirically, and making such determinations is within the skill in the art.
  • the dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms of the disorder are effected.
  • the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.
  • the dosage will vary with the age, condition, sex, and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art.
  • the dosage can be adjusted by the individual physician in the event of any counterindications.
  • Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.
  • Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
  • guidance in selecting appropriate doses for antibodies can be found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389.
  • a typical daily dosage of the adherent stromal cells used alone might range from about 10 million to about 500 million cells per administration, depending on the factors mentioned above.
  • the dosage of adherent stromal cells can be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 million cells or any amount in between.
  • a range of adherent stromal cells can be used including from about 10 to about 500 million cells, from about 100 to about 400 million cells, from about 150 to about 300 million cells.
  • a method of treating, inhibiting, or preventing GVHD in a subject in need thereof comprising administering to said subject a therapeutically or prophylactically effective amount of adherent stromal cells, wherein the dosage of adherent stromal cells administered to the subject is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 million cells or from about 150 million to about 300 million cells.
  • manufactured using said adherent stromal cells can be administered for a duration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, 1.5, 2, 3, 4, 5 years, or more.
  • the disclosed cells and compositions can be administered singly or in multiple administrations.
  • a method of treating GVHD and uses comprising administering the disclosed adherent stromal cells, medicaments, and/or compositions comprising said cells wherein the adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells are administered 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 24, 25, 30, 35, 36, 40, 45, 48, 50, 55, 60 or more times.
  • the adherent stromal cells or compositions comprising said cells may be administered at regular or variable intervals.
  • the adherent stromal cells or compositions comprising said cells may be administered regularly such that they or administered hourly, every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours; daily, every other day; every third day, weekly, every two weeks, monthly, or yearly.
  • cells or compositions comprising said cells can be administered according to the methods at irregular (i.e., variable intervals) such as, for example, a first dose, a second dose a week later, and a third dose a month following the first dose later; or a first dose followed by a second dose a month later and a third dose three months following the first dose; or doses at one week intervals for three months, followed by monthly intervals until the one year point, followed by yearly doses.
  • compositions can be administered before, after, concurrently with, or in combination with a graft when used in the disclosed methods and uses for treating GVHD.
  • the disclosed adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered 7, 6, 5, 4, 3, 2, days, 24, 23, 22, 21, 20, 19, , 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 hours, 45, 30, 15, 10, 5, 4, 3, 2, or 1 min or any combination thereof before administration of the graft in the disclosed methods and uses of treating GVHD.
  • the disclosed adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60min, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 20, 24, 25, 30, 36, 40, 45, 48, 50, 55, or 60 hours, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months or any combination thereof after administration of the graft or onset of GVHD in the disclosed methods and uses of treating GVHD.
  • adherent stromal cells, compositions comprising said adherent stromal cells, or medicament manufactured using said adherent stromal cells can be administered in combination before, concurrently with, and/or after administration of the graft in the disclosed methods and uses of treating GVHD.
  • adherent stromal cells or composition comprising adherent stromal cells administered in the methods or uses disclosed herein wherein the adherent stromal cells administered in a composition for treating, inhibiting, preventing GVHD further comprising an immunosuppressive agent, steroid, anti-inflammatory, small molecule, pharmaceutical, or other agent.
  • adherent stromal cells or composition comprising adherent stromal cells administered in the methods or uses disclosed herein wherein the adherent stromal cells administered in a composition for treating, inhibiting, preventing GVHD further comprising an immunosuppressive agent, steroid, anti-inflammatory, small molecule, pharmaceutical, or other agent.
  • adherent stromal cells or composition comprising adherent stromal cells administered in the methods or uses disclosed herein wherein the adherent stromal cells administered in a composition for treating, inhibiting, preventing GVHD further comprising an immunosuppressive agent, steroid, anti-inflammatory, small molecule, pharmaceutical, or other agent.
  • compositions comprising said cells can be in a further composition comprising topical therapy for skin rash; a calcineurin inhibitor; a corticosteroid; immunosuppressive treatment (e.g., methotrexate, cyclosporine, a corticosteroid, and/or anti-thymocyte globulin); anti-TNF alpha antibody; mammalian target of rapamycin (mTOR) inhibitor; mycophenolate mofetil, interleukin-2 receptor antibody; alemtuzumab pentostatin; and/or mesenchymal stem cells.
  • mTOR mammalian target of rapamycin
  • mycophenolate mofetil interleukin-2 receptor antibody
  • alemtuzumab pentostatin alemtuzumab pentostatin
  • mesenchymal stem cells e.g., mesenchymal stem cells.
  • adherent stromal cells e.g., PLX cells
  • the efficacy of the therapeutic composition comprising adherent stromal cells can be assessed in various ways well known to the skilled practitioner.
  • a composition such as a therapeutic composition comprising adherent stromal cells (e.g., PLX cells), disclosed herein is efficacious in treating, preventing, or inhibiting GVHD in a subject by observing that the composition reduces rashes, blistering, nausea, loss of apetite, dryness, jaundice, hair loss, scarring of lung, liver, or intestinal tract, diminished bile flow, or other symptoms of GVHD in the subject.
  • adherent stromal cells e.g., PLX cells
  • kits and articles of manufacture that are drawn to reagents that can be used in practicing the methods disclosed herein.
  • the kits and articles of manufacture can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods.
  • the kits and articles of manufacture may further comprise adherent stromal cells.
  • the kits and articles of manufacture may comprise a label, instructions, and packaging material.
  • a kit for or an article of manufacture comprising a packaging material which comprises a label for use in treating or preventing GVHD, said packaging material packaging a pharmaceutically effective amount of adherent stromal cells, wherein the cells are optionally obtained from placenta or adipose tissue.
  • kits or articles of manufacture which provide a means for extracting adherent cells from a donor source.
  • the kits or articles of manufacture can comprise 2D and/or 3D culturing instructions, growth media, and/or containers (such as a 3D bioreactor) for the propagation of adherent stromal cells.
  • models exist for acute and chronic GVHD.
  • models include MHC-mismatched models, MiHA-mismatched models, xenogenic transplant models, and antigen-specific transgenic models.
  • cGVHD chronic GVHD
  • mice are useful for performing mechanistic, kinetic, and therapeutic studies related to GVHD. Most knowledge of the role of the immune system GVHD comes from experiments in mice. Most animal GVHD models utilize whole body irradiation, otherwise known as myeloablative conditioning. Following lethal irradiation, animals are infused with T-cell-depleted bone marrow supplemented with donor lymphocytes (either splenocytes or lymph node T cells). The bone marrow enables hematopoietic reconstitution after transplant. T-cells are depleted from the bone marrow to control the number of immune cells that are delivered.
  • donor lymphocytes either splenocytes or lymph node T cells
  • mice that are major histocompatibility complex (MHC)-matched can vary by minor histocompatibility antigens (MiHAs) that influence aGVHD severity; (5) variation in environmental pathogens between labs.
  • MHC major histocompatibility complex
  • MiHAs minor histocompatibility antigens
  • NOD-scid IL-2Rynull mice are immunodeficient due to a mutation in the IL-2 receptor.
  • they engraft xenogeneic cells readily and can serve as a human-into-mouse xenogeneic GVHD model in which the engrafted cells are amenable to regulation by various therapies, including cell therapies.
  • Development of GVHD in this model is based on cell reactivity with foreign MHC class I and class II. This resembles HLA-mismatched
  • HSCT hematopoietic stem cell transplantation
  • C57BL to C57BL/6xBALB/c Fl mice serve as a semi-allogeneic BM
  • transplantation model This model mimics a haplo-identical transplantation (parent-to-child).
  • spleen cells from C57BL/6 donor mice are injected intravenously into irradiated C57BL/6 Balb/c Fl recipient mice.
  • GVHD develops two to three weeks posttransplantation and includes weight loss, hair loss, and sometimes diarrhea.
  • mice received a whole body lethal irradiation (lOOOrad) in a single dose, and one day after (at day 0) were transplanted with 8 x 10 6 C57BL/6 bone marrow cells and 10 x 10 6 spleen cells.
  • PLX cells were intramuscularly (IM) or intravenously (IV) injected into the mice at the day of transplantation (day 0), approximately 20 hours after irradiation, and at day 4. Intramuscular administration was performed by injecting 1 x 10 6 PLX cells in 50 ⁇ PlasmaLyte A for each animal or the same volume of vehicle (PlasmaLyte A) for group A control mice.
  • Intravenous administration of PLX cells (1 x 10 6 cells) at day 0 was performed through the tail vein after mixing 50 ⁇ of PLX suspension (1 x 10 6 cells) together with the BM and spleen cells in PlasmaLyte, reaching a total volume of 250 ⁇ .
  • 1 x 10 6 PLX cells were intravenously injected also at day 4 in a total volume of 250 ⁇ PlasmaLyte while the same volume of PlasmaLyte was administered to the control group.
  • mice The clinical condition of the mice was monitored every other day for up to six weeks after transplantation, and included monitoring of: 1) body weight, 2) fur loss, and 3) diarrhea.
  • GVHD score were calculated based on body weight, the size of the area of fur loss, and extent of diarrhea.
  • mice (10-11 weeks old Fl (Balb/c x C57BL/6) female mice) were purchased from Harlan. Animals were housed for 5 days in a specific pathogen free (SPF) facility for acclimation before treatment.
  • SPF pathogen free
  • mice were given lethal whole body irradiation by a single dose of 1000 rad. One day after irradiation, the mice received a transplant of 8 x 10 6 bone marrow cells and 10 x 10 6 spleen cells from C57BL/6 mice.
  • PLX cells were thawed and prepared for administration briefly as follows. Cells were removed from liquid nitrogen storage, thawed at 37 degrees C, and combined with a solution of human albumin in plasmaLyte A (one volume thawed cells combined with 10 volumes of a combination of 1 part human albumin 20% with 3 parts plasmaLyte A). The cells were gently centrifuged, resuspended in cold plasmaLyte A, recentrifuged, and finally resuspended in cold plasmaLyte A to a final cell concentration of 20 x 10 6 cells/ml.
  • PLX cells were intramuscularly or intravenously administered at days 0 and at day 4 as follows:
  • Intramuscular administration was performed by injecting 50 ⁇ of PLX cell suspension (1 x 10 6 cells) or PlasmaLyte A per animal, immediately after BM and spleen cells transplantation.
  • Intravenous administration was performed at day 0 by injecting 1 x 10 6 PLX cells in 50 ⁇ PlasmaLyte with bone marrow and spleen cells in PlasmaLyte to reach a total volume of 250 ⁇ .
  • 1 x 10 6 PLX cells were injected alone in a total volume of 250 ⁇ PlasmaLyte.
  • the cells were administered slowly via the tail vein (over 1-2 minutes), and the injection times were recorded.
  • mice received intramuscular administration with 50 ⁇ PlasmaLyte at days 0 (immediately after BM and spleen cell transplantation) and at day 4, while three other control mice received intravenous administration with bone marrow and spleen cells in 250 ⁇ PlasmaLyte at day 0 and 250 ⁇ PlasmaLyte only at day 4.
  • mice were monitored in SPF conditions by monitoring 1) body weight monitoring, 2) fur loss, and 3) diarrhea. Chimerism in the blood of 3 representative mice from each experimental group was also tested two weeks after transplantation using FACS for H-2Dd allele (expressed by balb/c only).
  • mice were sacrificed at 5-6 weeks following model induction / PLX
  • mice were sacrificed according to the rules of the ethical approval.
  • the parameters monitored were weight (% of initial weight) and GVHD score. Skin, liver, and colon samples were also collected for histology and were preserved in 10% neutral-buffered formalin for optional paraffin embedding.
  • PLX cell treatment improved the mice's recovery from irradiation and GVHD induction by C57BL/6 bone marrow and spleen cell transplantation.
  • Mice administered PLX cells either intramuscularly (IM) or intravenously (IV) recovered body weight more quickly and to a greater extent than control (vehicle-treated) mice ( Figure 1), and the PLX mice showed improved clinical conditions.
  • the IV mice improved slightly more quickly than the IM mice.
  • the body weight differences between all groups persisted until approximately four weeks after GVHD induction.
  • the rate of survival of PLX-treated mice was also slightly greater than control mice ( Figure 2A).
  • PLX treatment did not alter the rates of HLA chimerism in the mice ( Figure 2B).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour traiter la maladie du greffon contre l'hôte.
PCT/IB2014/059706 2013-03-14 2014-03-13 Méthode permettant de prévenir et de traiter la maladie du greffon contre l'hôte WO2014141111A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361781205P 2013-03-14 2013-03-14
US61/781,205 2013-03-14
US201361821253P 2013-05-09 2013-05-09
US61/821,253 2013-05-09

Publications (1)

Publication Number Publication Date
WO2014141111A1 true WO2014141111A1 (fr) 2014-09-18

Family

ID=50543260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059706 WO2014141111A1 (fr) 2013-03-14 2014-03-13 Méthode permettant de prévenir et de traiter la maladie du greffon contre l'hôte

Country Status (1)

Country Link
WO (1) WO2014141111A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669519B2 (en) 2010-10-08 2020-06-02 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP3883586A4 (fr) * 2019-03-27 2022-09-07 Pluristem Ltd. Procédés et compositions pour le traitement esthétique et cosmétique et la stimulation de la pousse des cheveux
US11608486B2 (en) 2015-07-02 2023-03-21 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11634677B2 (en) 2016-06-07 2023-04-25 Terumo Bct, Inc. Coating a bioreactor in a cell expansion system
US11667881B2 (en) 2014-09-26 2023-06-06 Terumo Bct, Inc. Scheduled feed
US11667876B2 (en) 2013-11-16 2023-06-06 Terumo Bct, Inc. Expanding cells in a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11795432B2 (en) 2014-03-25 2023-10-24 Terumo Bct, Inc. Passive replacement of media
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3610795A (en) 1968-10-17 1971-10-05 Intitut De Rech De La Siderurg Apparatus for continuously melting of metal
US5168085A (en) 1991-05-20 1992-12-01 Corning Incorporated Multi-stage twc system
US5266476A (en) 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US6197575B1 (en) 1998-03-18 2001-03-06 Massachusetts Institute Of Technology Vascularized perfused microtissue/micro-organ arrays
US6911201B1 (en) 1999-02-04 2005-06-28 Technion Research & Development Foundation Ltd. Method of producing undifferentiated hemopoietic stem cells using a stationary phase plug-flow bioreactor
WO2007108003A2 (fr) 2006-03-23 2007-09-27 Pluristem Ltd. Procedes de developpement cellulaire et utilisations therapeutiques des cellules et des milieux conditionnes produits de cette maniere
WO2008100498A2 (fr) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Traitement des maladies inflammatoires au moyen de cellules souches placentaires
WO2009037690A1 (fr) 2007-09-19 2009-03-26 Pluristem Ltd. Cellules adhérentes provenant de tissus adipeux ou placentaires et leur utilisation thérapeutique
WO2011064669A2 (fr) * 2009-11-30 2011-06-03 Pluristem Ltd. Cellules adhérentes du placenta et leur utilisation dans le traitement de pathologies

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3610795A (en) 1968-10-17 1971-10-05 Intitut De Rech De La Siderurg Apparatus for continuously melting of metal
US5266476A (en) 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5168085A (en) 1991-05-20 1992-12-01 Corning Incorporated Multi-stage twc system
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US6139578A (en) 1995-05-19 2000-10-31 Etex Corporation Preparation of cell seeded ceramic compositions
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US6277151B1 (en) 1995-05-19 2001-08-21 Etex Corporation Cartilage growth from cell seeded ceramic compositions
US6197575B1 (en) 1998-03-18 2001-03-06 Massachusetts Institute Of Technology Vascularized perfused microtissue/micro-organ arrays
US6911201B1 (en) 1999-02-04 2005-06-28 Technion Research & Development Foundation Ltd. Method of producing undifferentiated hemopoietic stem cells using a stationary phase plug-flow bioreactor
WO2007108003A2 (fr) 2006-03-23 2007-09-27 Pluristem Ltd. Procedes de developpement cellulaire et utilisations therapeutiques des cellules et des milieux conditionnes produits de cette maniere
WO2008100498A2 (fr) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Traitement des maladies inflammatoires au moyen de cellules souches placentaires
WO2009037690A1 (fr) 2007-09-19 2009-03-26 Pluristem Ltd. Cellules adhérentes provenant de tissus adipeux ou placentaires et leur utilisation thérapeutique
US20100209403A1 (en) 2007-09-19 2010-08-19 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
WO2011064669A2 (fr) * 2009-11-30 2011-06-03 Pluristem Ltd. Cellules adhérentes du placenta et leur utilisation dans le traitement de pathologies

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
A.R. GENNARO,: "REMINGTON The Science and Practice of Pharmacy (19th ed.)", 1995, MACK PUBLISHING COMPANY
ALI, N. ET AL.: "Xenogeneic graft-versus-host-disease in NOD-scid lL-2Rgammanull mice display a T-effector memory phenotype", PLOS ONE, vol. 7, no. 8, 2012, pages E44219
BAGSHAWE ET AL., BR. J. CANCER, vol. 58, 1988, pages 700 - 703
BAGSHAWE, K.D., BR. J. CANCER, vol. 60, 1989, pages 275 - 281
BATTELLI ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 35, 1992, pages 421 - 425
BROWN; GREENE, DNA AND CELL BIOLOGY, vol. 10, no. 6, 1991, pages 399 - 409
CAHN, J.Y. ET AL.: "Prospective evaluation of2 acute graft-versus-host (GvHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study", BLOOD, vol. 106, no. 4, 2005, pages 1495 - 500
CANAPLE L. ET AL.: "Improving cell encapsulation through size control", J BIOMATER SCI POLYM ED., vol. 13, 2002, pages 783 - 96
CASTOR, M.G.; V. PINHO; M.M. TEIXEIRA: "The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics", FRONT PHARMACO1, vol. 3, 2012, pages 23
CHANG TM; PRAKASH S: "Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms", MOL BIOTECHNOL., vol. 17, 2001, pages 249 - 60
CHIA, S.M. ET AL.: "Multi-layered microcapsules for cell encapsulation", BIOMATERIALS, vol. 23, 2002, pages 849 - 56, XP004322709, DOI: doi:10.1016/S0142-9612(01)00191-0
DESAI, T.A.: "Microfabrication technology for pancreatic cell encapsulation", EXPERT OPIN BIOL THER., vol. 2, 2002, pages 633 - 46
DIGNAN, F.L. ET AL.: "Diagnosis and management of acute graft-versus-host disease", BR J HAEMATOL, vol. 158, no. 1, 2012, pages 30 - 45
FERRONE ET AL.,: "Handbook of Monoclonal Antibodies", 1985, NOGES PUBLICATIONS, pages: 303 - 357
GLUCKSBERG, H. ET AL.: "Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors", TRANSPLANTATION, vol. 18, no. 4, 1974, pages 295 - 304
HUGHES ET AL., CANCER RESEARCH, vol. 49, 1989, pages 6214 - 6220
ILAN, Y. ET AL.: "Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity", TRANSPLANTATION, vol. 83, no. 4, 2007, pages 458 - 67
INAMOTO, Y.; M.E. FLOWERS: "Treatment of chronic graft-versus-host disease in 2011", CURR OPIN HEMATOL, vol. 18, no. 6, 2011, pages 414 - 20
KITAGAWA ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 93, no. 5, 2006, pages 947 - 954
LI CHANG DONG ET AL: "MESENCHYMAL STEM CELLS DERIVED FROM HUMAN PLACENTA SUPPRESS ALLOGENEIC UMBILICAL CORD BLOOD LYMPHOCYTE PROLIFERATION", CELL RESEARCH - XIBAO YANJIU, NATURE PUBLISHING GROUP, GB, CN, vol. 15, no. 7, July 2005 (2005-07-01), pages 539 - 547, XP009080356, ISSN: 1001-0602, DOI: 10.1038/SJ.CR.7290323 *
LITZINGER; HUANG, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1104, 1992, pages 179 - 187
LU MZ ET AL.: "A novel cell encapsulation method using photosensitive poly(allylamine alpha-cyanocinnamylideneacetate", J MICROENCAPSUL., vol. 17, 2000, pages 245 - 51
LU MZ ET AL.: "Cell encapsulation with alginate and alpha- phenoxycinnamylidene-acetylated poly(allylamine", BIOTECHNOL BIOENG., vol. 70, 2000, pages 479 - 83, XP008025769, DOI: doi:10.1002/1097-0290(20001205)70:5<479::AID-BIT1>3.0.CO;2-E
OLLE RINGDÉN ET AL: "Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease", STEM CELLS, vol. 31, no. 3, 10 January 2013 (2013-01-10), pages 592 - 601, XP055117619, ISSN: 1066-5099, DOI: 10.1002/stem.1314 *
OR REUVEN ET AL: "Correction of Post-Transplant Hematopoiesis by Novel Use of Mesenchymal-Like Placental Expanded Cells (PLX) Administered Intra-Muscular", BLOOD, vol. 120, no. 21, November 2012 (2012-11-01), & 54TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ATLANTA, GA, USA; DECEMBER 08 -11, 2012, pages 4133, XP002724271 *
PEREZ, L.; C. ANASETTI; J. PIDALA: "Have we improved in preventing and treating acute graft-versus-host disease?", CURR OPIN HEMATOL, vol. 18, no. 6, 2011, pages 408 - 13
PIETERSZ; MCKENZIE, IMMUNOLOG. REVIEWS, vol. 129, 1992, pages 57 - 80
PRZEPIORKA, D. ET AL.: "Consensus Conference on Acute GVHD Grading", BONE MARROW TRANSPLANT, vol. 15, no. 6, 1994, pages 825 - 8, XP009166128
ROFFLER ET AL., BIOCHEM. PHARMACOL, vol. 42, 1991, pages 2062 - 2065
ROWLINGS, P.A. ET AL.: "IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade", BR J HAEMATOL, vol. 97, no. 4, 1997, pages 855 - 64
SAMBANIS, A.: "Encapsulated islets in diabetes treatment", DIABETES TECHNOL. THER., vol. 5, 2003, pages 665 - 8
SENTER ET AL., BIOCONJUGATE CHEM., vol. 2, 1991, pages 447 - 451
SENTER ET AL., BIOCONJUGATE CHEM., vol. 4, 1993, pages 3 - 9
SMITH ET AL.: "Antibodies in Human Diagnosis and Therapy", 1977, RAVEN PRESS, pages: 365 - 389
ULUDAG, H. ET AL.: "Technology of mammalian cell encapsulation", ADV DRUG DELIV REV., vol. 42, 2000, pages 29 - 64, XP002302229, DOI: doi:10.1016/S0169-409X(00)00053-3
WENDT, D. ET AL., BIOTECHNOL BIOENG, vol. 84, 2003, pages 205 - 214
WILLIAMS D.: "Small is beautiful: microparticle and nanoparticle technology in medical devices", MED DEVICE TECHNOL., vol. 10, 1999, pages 6 - 9

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870827B2 (en) 2010-10-08 2020-12-22 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US10669519B2 (en) 2010-10-08 2020-06-02 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11613727B2 (en) 2010-10-08 2023-03-28 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11773363B2 (en) 2010-10-08 2023-10-03 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US11667876B2 (en) 2013-11-16 2023-06-06 Terumo Bct, Inc. Expanding cells in a bioreactor
US11708554B2 (en) 2013-11-16 2023-07-25 Terumo Bct, Inc. Expanding cells in a bioreactor
US11795432B2 (en) 2014-03-25 2023-10-24 Terumo Bct, Inc. Passive replacement of media
US12065637B2 (en) 2014-09-26 2024-08-20 Terumo Bct, Inc. Scheduled feed
US11667881B2 (en) 2014-09-26 2023-06-06 Terumo Bct, Inc. Scheduled feed
US11608486B2 (en) 2015-07-02 2023-03-21 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11634677B2 (en) 2016-06-07 2023-04-25 Terumo Bct, Inc. Coating a bioreactor in a cell expansion system
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12077739B2 (en) 2016-06-07 2024-09-03 Terumo Bct, Inc. Coating a bioreactor in a cell expansion system
US11999929B2 (en) 2016-06-07 2024-06-04 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US12359170B2 (en) 2017-03-31 2025-07-15 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3883586A4 (fr) * 2019-03-27 2022-09-07 Pluristem Ltd. Procédés et compositions pour le traitement esthétique et cosmétique et la stimulation de la pousse des cheveux
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly

Similar Documents

Publication Publication Date Title
WO2014141111A1 (fr) Méthode permettant de prévenir et de traiter la maladie du greffon contre l&#39;hôte
EP2626417B1 (fr) Procédés de développement cellulaire et utilisations thérapeutiques des cellules et des milieux conditionnés produits de cette maniere
US10722541B2 (en) Methods for treating radiation or chemical injury
US20110293583A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110171182A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20140017209A1 (en) Methods for treating radiation or chemical injury
HK1187950B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1160174B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1177759B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1136846B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1188812A (en) Methods for treating radiation or chemical injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718747

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14718747

Country of ref document: EP

Kind code of ref document: A1